Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of small molecule antibiotics for difficult‑to‑treat bacterial ...
STATEN ISLAND, N.Y., Oct. 28, 2025 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (ACXP) ("Acurx" or the "Company"), is a late-stage biopharmaceutical company developing a new class of antibiotics for ...
Acurx Pharmaceuticals’ DNA Polymerase IIIC inhibitors receives US patent: Staten Island, New York Wednesday, February 4, 2026, 15:00 Hrs [IST] Acurx Pharmaceuticals, Inc., a lat ...
CAMBRIDGE, United Kingdom and NEW YORK, October 13, 2025 – Artios Pharma Limited (“Artios”), a biopharmaceutical company committed to realizing the therapeutic power of targeting the DNA damage ...
The cancer drugs called PARP inhibitors have a puzzling reputation: even though they are treatment mainstays for multiple forms of cancer, they can damage cancer-killing T cells and disrupt the ...
Clinical and Preclinical Activity of EGFR Tyrosine Kinase Inhibitors in Non–Small-Cell Lung Cancer Harboring BRAF Class 3 Mutations This was a phase II multicenter trial in which refractory solid ...
Humans and baker's yeast have more in common than meets the eye, including an important mechanism that helps ensure DNA is copied correctly, reports a pair of studies. The findings visualize for the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results